Orient Europharma Group’s promising subsidiary Orient Pharma is scheduled to be listed on the Taipei OTC market in late August, with a tentative underwriting price of NT$28.04. Orient Pharma held a pre-OTC performance briefing on July 29. General Manager Chun-Tung Huang stated on July 28 that Orient Pharma focuses on three major technology platforms and is actively investing in core areas such as cardiovascular and central nervous system diseases. The company currently has three marketed drugs and plans to launch four new products, including an anti-Alzheimer’s drug, over the next four years starting this year.
In the first half of this year, Orient Pharma reported consolidated revenue of NT$642 million, a year-on-year increase of 6.91%. Net profit after tax in Q1 reached NT$50.57 million, up 33% year-on-year, with earnings per share of NT$0.23. Chairman Peter Tsai noted that last year’s revenue was NT$1.223 billion, with product sales accounting for NT$1.02 billion or 83.14% of total revenue, serving as the primary driver of operations. Meanwhile, income from licensing and royalties totaled about NT$147 million, or 12.06% of total revenue, reflecting the commercial value of the company’s long-term R&D achievements.
Tsai emphasized that Orient Pharma continues to deepen its 505(b)(2) new drug development strategy and will keep delivering quality products. Beyond Taiwan, Orient Europharma is among the earliest companies to establish a foothold in Southeast Asia, currently operating four subsidiaries in the region. The next expansion steps include Australia and New Zealand, with plans to enter European and American markets through distributors.
Huang highlighted the strong performance of Orient Pharma’s innovative ADHD drug Methydur (Si You De), which has been covered by Taiwan’s National Health Insurance since 2020 and classified as a Category 2A new drug. In addition to solid domestic sales, Orient Pharma has achieved tangible results internationally. Its generic diabetes drug has secured FDA approval for marketing in the U.S., making Orient Pharma the first Taiwanese company to obtain this category of drug approval, with stable market entry achieved. The oral antibiotic Vancomycin has also surpassed competing drugs of the same ingredient in U.S. market share since launch.
Orient Pharma’s R&D focuses on 505(b)(2) new drugs with high barriers to entry and patent protection, alongside niche generic drugs. To establish strong market barriers, Orient Pharma has built three core formulation platforms: SMRT (Semi-Solid Multi-layer Release Technology), MUPS (Multiple Unit Pellet System), and OROS (Osmotic Controlled Release Oral Delivery System).
Huang projected that between 2025 and 2028, Orient Pharma will launch four new products, including a high-dose lipid-lowering drug already approved, a rheumatoid arthritis drug submitted in 2025, a novel combination Alzheimer’s drug, and a pulmonary fibrosis treatment. These launches are expected to drive explosive growth in the company’s performance starting in 2027.
Resource: 友華集團小金雞友霖轉上櫃 未來推出抗阿茲海默症新藥
